Skip to main content
Elsevier
View Cart

Recent Developments in Anti-Inflammatory Therapy

  • 1st Edition - February 17, 2023
  • Latest edition
  • Editors: Parteek Prasher, Flavia Zacconi, Kamal Dua, Michael Rathbone, Jeffrey Withey
  • Language: English

Advances in Anti-inflammatory Therapy explores the cutting-edge in anti-inflammation therapy in clear and concise language, with insights from academia and industry. Sections… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

Advances in Anti-inflammatory Therapy explores the cutting-edge in anti-inflammation therapy in clear and concise language, with insights from academia and industry. Sections cover key regulatory pathways that mediate acute and chronic inflammation and disease onset. Further chapters are devoted to advanced anti-inflammatory pharmaceuticals, including chemical moieties, pharmacophores, APIs, natural products, herbal therapies, molecular nanomedicine and advanced drug delivery vectors. Systematically planned chapters and illustrations enable potential readers to gain essential insights on the most recent advancements in the field.

Arranged with systematic chapters covering a broad range of inflammatory diseases, discussions on past, current and future therapeutics and advanced anti-inflammatory pharmaceuticals, this book will be useful to a wide range of researchers, especially medicinal chemists, drug design experts, and biological and translational researchers working in the field of inflammation.

Key features

  • Identifies recent developments and current trends in anti-inflammation therapy
  • Discusses advanced chemotherapeutics, SAR analysis of novel pharmacophores and natural products
  • Outlines the pathophysiology of inflammatory pathways in the pathogenesis of disease onset, including strategies to counter these intricacies
  • Contains a blend of editors from both academia and industry

Readership

Pharmaceutical Scientists and those who are working in or studying fundamental and translational research of therapeutics; Academics, researchers, clinicians and students from a wide range of fields including medicine, biological sciences, chemistry and pharmacology with an interest in inflammation

Table of contents

1. Pathophysiology and pathogenesis of inflammation

2. Autoimmunity and inflammation

3. Regulatory Pathways of inflammation

4. Advanced nanomedicine-based therapeutics for targeting airway inflammatory diseases

5. Advanced Therapeutics for targeting gut inflammation

6. Advanced Therapeutics for renal inflammation

7. Advanced Therapeutics for targeting inflammatory arthritis

8. Advanced Therapeutics for targeting atherosclerosis

9. Targeting vascular inflammation in atherosclerosis with advanced therapeutics

10. Targeting cancer-inducing inflammation: Recent advancement and future prospects

11. Interplay between Gut Microbiota, Immune Homeostasis and Inflammatory Diseases

12. Advanced Drug delivery systems in inflammation

13. Advanced nanoparticles or nanoparticulate system for the treatment of Anti-inflammatory diseases

14. Theranostics in targeting inflammation in chronic diseases

15. Natural Product based anti-inflammatory agents

16. Mechanism of anti-inflammatory effects of various natural derived secondary metabolites

17. Herbal Bioactive Based Anti-Inflammatory Formulations for Topical Administration

18. Flavonoids in the treatment of inflammation

19. Heterocycles in the treatment of inflammation

20. In vivo models of understanding inflammation (In vivo methods for inflammation)

21. Clinical trials and Future Perspectives of anti-inflammatory agents

Review quotes

"...provide[s] a deep understanding of the pathophysiology of inflammation, presenting an overview of inflammation and its regulatory pathways, different inflammatory diseases and their management, and the latest developments in anti-inflammatory therapies. [A] unique overview [that] contains many tables, schemes, and color illustrations to support the text. [A] welcome addition to the field, providing an up-to-date overview of state-of- the-art management of various inflammatory diseases and a fresh perspective of upcoming technologies. Written in a straightforward and concise manner, the book is a high-quality print that is enjoyable to read. [A] valuable addition to existing books in this area."—©Doody’s Review Service, 2023, Marc A Ilies, PhD (Temple University School of Pharmacy)

Product details

  • Edition: 1
  • Latest edition
  • Published: February 17, 2023
  • Language: English

About the editors

PP

Parteek Prasher

Dr Prasher, Assistant Professor, Department of Chemistry, University of Petroleum & Energy Studies, has research experience of 8 years in medicinal chemistry and biomaterials, while working in the field of anti-inflammatory and anticancer chemotherapy. The research team led by Dr. Prasher focuses on the development of rationally designed molecules for targeting various disorders, including inflammation, cancer, and antimicrobial MDR, which also includes the Identification of novel pharmacophores, chemical moieties and APIs for developing the potential chemotherapeutics. With inspiring national/ international collaborations, Dr. Prasher has published more than 45 peer reviewed publications, and >10 book chapters in the journals of repute. Dr. Prasher serves as reviewer for reputed journals published by Elsevier, ACS, RSC and Springer publishers, with the status “Recognized reviewer”. Dr. Prasher has been a recipient of the prestigious Junior/ Senior Research Fellowship by the Council of Scientific and Industrial Research, Government of India (2012-2015). Dr. Prasher received ‘Lectureship’ award by the Government of India (2012).
Affiliations and expertise
Assistant Professor, Department of Chemistry, University of Petroleum and Energy Studies, India

FZ

Flavia Zacconi

In 2012, Prof. Zacconi became Assistant Professor in the Faculty of Chemistry at Pontificia Universidad Católica de Chile (Chile). Currently, her Associate Professor position is shared between the Faculty of Chemistry and Pharmacy and the Institute for Biological and Medical Engineering (IIBM). Moreover, Dr. Zacconi has a research experience of more than 11 years in organic chemistry, medicinal chemistry and biomaterials, while working in the field of chemical synthesis, structural analyses, drug design, and materials. Dr. Zacconi’s research focuses on the intersections of organic chemistry, medicinal chemistry, engineering and biological chemistry, developing multi- and interdisciplinary research to understand the complexity in the design, synthesis and biological evaluation of bioactive compounds. Besides, Prof. Zacconi is an Associate Researcher at the Research Center for Nanotechnology and Advanced Materials (CIEN-UC). Additionally, Dr. Zacconi acts as a reviewer for international journals and she has published research papers, book chapters, books and reviews.
Affiliations and expertise
Associate Professor, Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile (PUC), Chile

KD

Kamal Dua

Kamal Dua is a Professor in the NICM Health Research Institute and the School of Science at Western Sydney University (WSU). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2026, 2025 and 2024 in Research Magazine by “The Australian” in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2026, 2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

Affiliations and expertise
Professor in the NICM Health Research Institute and the School of Science at Western Sydney University (WSU)

MR

Michael Rathbone

Michael J. Rathbone is founder and managing director of his own company, ULTI Pharmaceuticals, New Zealand. He is also an associate of the School, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia. He was formerly professor of Pharmaceutical Technology and dean, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia. Prior to this he was associate professor of Pharmaceutics, School of Pharmacy, Griffith University, Australia where his responsibilities included Acting Head of School. Previous to his appointment at Griffith University, he was the director of Research and General Manager InterAg, New Zealand, where he spearheaded the companies veterinary controlled drug delivery research and directed their national and global collaborative research activities. Dr. Rathbone obtained his undergraduate degree in Pharmacy at Leicester Polytechnic (De Montfort University), UK (1980), and PhD in Pharmaceutics from the University of Aston, Birmingham, UK (1986). Dr. Rathbone has innovated many novel veterinary drug delivery systems, several of which have been registered on the New Zealand, Australian and United States markets. He is a fellow of the Controlled Release Society, has served on the Board of Directors of the CRS and has received several prestigious awards for his contribution to the science and technology of controlled release. He has edited eight books in the area of modified release drug delivery and 10 special theme issues of journals such as Advanced Drug Delivery Reviews and Journal of Controlled Release. His knowledge of the entire spectrum of innovation, product research & development, cGMP analysis, manufacturing scale-up, QC analysis, stability testing, and registration provides him with an extensive overview, and unparalleled experience of the veterinary pharmaceutical industry.
Affiliations and expertise
ULTI Pharmaceuticals, Turangi, New Zealand

JW

Jeffrey Withey

Professor Jeffrey Withey, PhD, has worked in the infectious diseases field for over 19 years and has held a faculty position at Wayne State University since 2006. Dr. Withey earned a Bachelor’s degree in Biology from Johns Hopkins University in 1991 and a PhD in Cellular and Molecular Biology from the University of Michigan in 2000. Dr. Withey has been awarded numerous grants from the US NIH and the Gates Foundation to fund his research. Dr. Withey was a Fulbright Scholar in 2014-2015 and was selected as a Fulbright Alumni Ambassador for 2020-2022. Dr. Withey is currently an Associate Editor for PLoS Neglected Tropical Diseases, and on the Editorial boards for Journal of Bacteriology, Infection and Immunity, Journal of Microbiological Methods, and Current Clinical Microbiology Reports. He has served on numerous grant review panels for NIH and international funding agencies and published nearly 40 research papers and several book chapters.
Affiliations and expertise
Professor, Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, USA

View book on ScienceDirect

Read Recent Developments in Anti-Inflammatory Therapy on ScienceDirect